ALZN - Company ID 0001677077
Alzamend Neuro, Inc. trades as ALZN. This page tracks Alzamend Neuro, Inc. through 374 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Next research step
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-04-17 |
| Insider trade | 4 | 2026-04-16 |
| Major company event | 8-K | 2026-03-20 |
| Quarterly report | 10-Q | 2026-03-11 |
| Prospectus supplement | 424B5 | 2026-03-06 |
| Major company event | 8-K | 2026-03-06 |
| Proxy materials | DEFA14A | 2026-02-26 |
| Proxy statement | DEF 14A | 2026-02-26 |
The largest companies sharing Alzamend Neuro, Inc.'s SEC industry classification (pharmaceutical preparations).
In its latest fiscal year Alzamend Neuro, Inc. reported a net loss of $4.51M.